As Tecentriq Growth Slows, Roche’s Imminent TIGIT Readout Is Crucial
Aims To Challenge Keytruda Dominance
Executive Summary
One of the year’s most important trial readouts is for Roche’s potential first-in-class TIGIT inhibitor, tiragolumab, and could help reverse a slowdown in blockbuster immunotherapy Tecentriq's growth.
You may also be interested in...
Novartis/BeiGene Likely To Struggle In Crowded PD-1 Space Despite Positive First-Line Data
Merck’s Keytruda and BMS’s Opdivo could be tough competitors in esophageal cancer, but the Novartis/BeiGene partnership also has an anti-TIGIT drug up its sleeve.
AstraZeneca Uses Priority Voucher To Speed Combo Towards Liver Cancer Approval
AstraZeneca’s PD-L1/CTLA-4 combination could soon be rivalling Roche’s regimen, and may offer greater safety and tolerability for liver cancer patients.
Roche's SERD Setback Means Menarini Retains An Edge
Roche's giredestrant failed to show a benefit on progression-free survival in the Phase II acelERA trial in people with advanced breast cancer.